Clinical trials: Cellular Senescence
Hepatitis A Vaccine
Phase Ⅲ Clinical Trial of an Inactivated Hepatitis A Vaccine
This is a Phase Ⅲ, open-label, single arm design combined with randomized, double-blind, active-controlled design trial to assess the immunogenicity and safety of different specifications of Healive® (the 0.5 mL pediatric dosage…
- Trial name
- NCT07793227
- Testing
- Inactivated Hepatitis A Vaccine (Human Diploid Cell) (1 mL), Inactivated Hepatitis A Vaccine (Human Diploid Cell) (0.5 mL), Hepatitis A vaccine (inactivated, adsorbed)
- Where
- Vietnam
- Volunteers
- 680 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Coronavirus Disease 2019
Clinical Study on the Immune Program of Recombinant Novel Coronavirus（COVID-19) Vaccine (CHO Cell)
Popular topic：Clinical study on the immune program of recombinant Novel Coronavirus (COVID-19) vaccine (CHO cell). Research purpose:Main purpose: To evaluate the immunogenicity of recombinant novel coronavirus vaccine (CHO cells)…
- Trial name
- NCT05128643
- Testing
- Recombinant novel coronavirus vaccine (CHO cell)
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Improvement in Immune Cell Function in Elderly Humans
GSH Supplementation on Cold/Flu Symptoms in Older Healthy Adults
A randomized, double blind placebo-controlled parallel intervention in adults over the age of 50 will be performed. Participants will receive a supplement capsule containing placebo (Crystalline Cellulose) or 500mg of Setria®…
- Trial name
- NCT02316925
- Testing
- Setria glutathione supplement, Crystalline Cellulose
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Florida
Non-small Cell Lung Carcinoma
Hypermetabolism in the Elderly Lung Cancer Patient
Aging and cancer are two conditions associated with extensive metabolic changes that can cause malnutrition. However, the clinical features and the underlying mechanisms leading to malnutrition are different in these two cases.
- Trial name
- HELP (NCT03141957)
- Where
- France
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- University of Paris 5 - Rene Descartes
Prevention of COVID-19 Caused by SARS-CoV-2
An Investigator Initiated, Randomized, Double-blinded, Placebo-controlled Clinical Trial to Evaluate the Safety, Immunogenicity and Efficacy of the Recombinant Two-component COVID-19 Vaccine (CHO Cell) in Adults Aged 18 Years and Older
Study Objective(s) To evaluate the safety, immunogenicity and protective efficacy of 1 dose of ReCOV in participants who have received 2 or 3 doses of inactivated SARS-CoV-2 vaccination in Chinese adults aged 18 years and older.
- Trial name
- NCT05679466
- Where
- China
- Volunteers
- 3,300 people, healthy volunteers welcome
- Sponsor
- Yu Qin
COVID-19
Immunogenicity and Safety of Recombinant COVID-19 Vaccine (CHO Cells)
This is a phase Ⅱ, randomized, placebo-controlled, double-blind study, to evaluate immunogenicity and safety of a recombinant COVID-19 vaccine (CHO cells) in the subjects from healthy adults and elderly adults aged 18 years and…
- Trial name
- NCT04813562
- Testing
- a middle-dose recombinant COVID-19 vaccine (CHO Cell) (18-59 years) at the schedule of day 0, 28, 56, a high-dose recombinant COVID-19 vaccine (CHO Cell) (18-59 years) at the schedule of day 0, 28, 56, a middle-dose recombinant COVID-19 vaccine (CHO Cell) (60-85 years) at the schedule of day 0, 28, 56
- Where
- China
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Coronavirus
Recombinant New Coronavirus Vaccine (CHO Cells) to Prevent SARS-CoV-2 Phase I Clinical Trial (≥60 Years Old)
Popular topic: Phase I clinical trial of recombinant new coronavirus vaccine (CHO cell) (≥60 years old) Research purpose: Main purpose: To evaluate the safety and tolerability of different doses of recombinant new coronavirus…
- Trial name
- NCT04550351
- Testing
- Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cell) low-dose group, Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cells) high-dose group
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Renal Cell Carcinoma (Kidney Cancer), Kidney Cancers
Targeted Abdominal CT in Conjunction With Lung Cancer Screening
Early detection through screening can improve cancer survival by identifying it when it's most treatable. The NHS now offers Lung Cancer Screening (LCS) assessments to people aged 55-74 who have ever smoked.
- Conditions
- Renal Cell Carcinoma (Kidney Cancer), Kidney Cancers, AAA - Abdominal Aortic Aneurysm, Renal Stones
- Trial name
- TACTICAL1 (NCT07171190)
- Testing
- Lung Cancer Screening Invitation Intervention, Abdominal scan intervention
- Where
- United Kingdom
- Volunteers
- 6,272 people, healthy volunteers welcome
- Sponsor
- University of Cambridge
Herpes Zoster
Month 30 & 42 Extension Studies of CRD-004 Primary Study
The safety and immunogenicity of the GSK324332A vaccine has been evaluated up to Month 12 post-vaccination in the primary study.
- Trial name
- NCT00492648
- Testing
- Blood sampling for assay of persistence of immunogenicity
- Where
- Belgium
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Safety and Immunogenicity of One Dose of a Surface, Antigen, Inactivated, Influenza Vaccine Produced in Mammalian Cell Culture Administered to Adult and Elderly Subjects
This study will evaluate safety and immunogenicity of surface, antigen, inactivated, influenza vaccine produced in mammalian cell culture when administered to adult and elderly subject.
- Trial name
- NCT01422512
- Testing
- seasonal influenza vaccine
- Where
- Germany
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Improvement in Immune Cell Function in Elderly Humans
Oral Glutathione Supplementation in Older Healthy Adults and Its Effect on the Number of Healthy Days Experienced During Four Months of Supplementation Compared to Placebo
A randomized, double blind placebo-controlled parallel intervention in adults over the age of 50 will be performed. Participants will receive a supplement capsule containing placebo (Crystalline Cellulose) or 500mg of Setria®…
- Trial name
- GSH (NCT02438956)
- Testing
- Setria glutathione supplement, Crystalline Cellulose
- Where
- United States
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- University of Florida
Influenza
Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older
The purpose of this study is to demonstrate the effectiveness (seroprotection and seroconversion as measured by the hemagglutination inhibition [HI] assay) of an investigational Vero cell-derived, trivalent, seasonal influenza…
- Trial name
- NCT00782431
- Testing
- Vero cell derived, trivalent, seasonal influenza vaccine, Licensed egg-derived, trivalent seasonal influenza vaccine
- Where
- 30 sites in United States
- Volunteers
- 3,208 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Influenza
Second Extension Study to Evaluate Safety and Tolerability of Influenza Vaccines in Adults and Elderly, and to Evaluate Immunogenicity and Concomitant Vaccination With Pneumococcal Vaccine in a Subgroup
The study primarily aims to evaluate immunogenicity and safety of influenza vaccines (cell culture derived seasonal trivalent influenza vaccine (cTIV) or influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free…
- Trial name
- NCT00579345
- Testing
- Cell culture derived seasonal trivalent influenza vaccine (cTIV), Influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a)., cTIV or eTIV_a
- Where
- 5 sites in Poland
- Volunteers
- 1,522 people, healthy volunteers welcome
- Sponsor
- Novartis
COVID-19
Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Children and Adolescents
This study is a multi-center and open design, phase Ⅳ clinical trial of an inactivated SARS-CoV-2 vaccine (CoronaVac) manufactured by Sinovac Research and Development Co., Ltd.The purpose of this study is to evaluate the safety…
- Trial name
- NCT04992208
- Testing
- Experimental Group
- Where
- China
- Volunteers
- 31,041 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
Influenza, Human
Immunogenicity and Safety of Quadrivalent Influenza Vaccine in Children and Adolescents
This study is a multi-center, randomized, double-blind Phase III clinical trial. The aim of the study is to describe the immunogenicity and safety of the quadrivalent cell culture-derived influenza vaccine compared to the…
- Trial name
- NCT02621164
- Testing
- NBP607-QIV, Agrippal S1
- Volunteers
- 454 people, healthy volunteers welcome
- Sponsor
- SK Chemicals Co., Ltd.
Multiple Myeloma
Patient and Care Partner Experiences Living With Multiple Myeloma (PaCE-MM)
This research study is explore the impact over time of multiple myeloma and its associated treatments on the physical and cognitive function and quality of life of patients and their care partners and how these impacts affect the…
- Trial name
- PaCE-MM (NCT05276622)
- Testing
- Comprehensive Geriatric Assessment, Qualitative patient-care partner interviews, Surveys on well-being and function
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Asherman's Syndrome, Thin Endometrial Lining
Senescent Endometrial Cells in Patients With Thin Endometrial Lining
The goal of this observational study is to determine if thin endometrial lining that is unresponsive to estrogen might be associated with the presence of senescent cells in patients following long-term use of oral contraceptives.
- Conditions
- Asherman's Syndrome, Thin Endometrial Lining, Cell Senescence
- Trial name
- NCT06450301
- Testing
- Endometrial Biopsy
- Where
- Canada
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Trio Fertility
Herpes Zoster (HZ), Shingles
A Immunogenicity and Safety Trial of the Recombinant Zoster Vaccine （CHO Cell）, LYB004 in Adults Aged 40 Years and Older
This phase 2 study in China will evaluate the immunogenicity and safety of the Recombinant Zoster Vaccine, LYB004 in adults aged 40 years and older.
- Conditions
- Herpes Zoster (HZ), Shingles, VZV, Recombinant Zoster Vaccine
- Trial name
- NCT07311148
- Testing
- Low dose antigen and low dose adjuvant of LYB004, Low dose antigen and high dose adjuvant of LYB004, High dose antigen and low dose adjuvant of LYB004
- Where
- China
- Volunteers
- 840 people, healthy volunteers welcome
- Sponsor
- Guangzhou Patronus Biotech Co., Ltd.
Influenza
Immunogenicity and Safety of a Cell-derived Influenza Vaccine in Adults Aged >= 18 and <= 64, Plus Revaccination
Immunogenicity and safety of a cell-derived influenza vaccine in adults aged >= 18 and <= 64 years, plus revaccination
- Trial name
- NCT00889889
- Testing
- Cell-Derived Trivalent Subunit Influenza Vaccine
- Where
- 15 sites in United States
- Volunteers
- 1,270 people, healthy volunteers welcome
- Sponsor
- Abbott Biologicals
Influenza, Avian Influenza
Immunogenicity and Safety Study of a Single Prime-Boost Vaccination Schedule With a H5N1 Influenza Vaccine in Adults
The main objective of the study is to assess the immune response to a non-adjuvanted H5N1 influenza vaccine in an adult population when administered according to a single prime-boost schedule.
- Trial name
- NCT00895544
- Testing
- Influenza vaccine (whole virion, Vero cell derived)
- Where
- 3 sites in Austria, Finland
- Volunteers
- 231 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.